1. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association Work Group on Schizophrenia. Practice Guideline for the Treatment of Patients With Schizophrenia. Second Edition. Arlington, VA: American Psychiatric Association, 2010. Web.  Accessed 10 Nov 2015.

2. Bayle FJ, Tessier A, Bouju S, Misdrahi D. Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone. Patient Prefer Adherence. 2015; 9:1333-41. 

3. Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014 Oct; 4(5):198-219.

4. Citrome L. New second-generation long-acting injectable antipyschotics for the treatment of schizophrenia. Expert Rev Neurother. 2013 Jul;13(7):767-83.

5. Hamann J, Lipp ML, Christ-Zapp S, Spellmann I, Kissling W. Psychiatrist and patient responses to suspected medication nonadherence in schizophrenia spectrum disorders. Psychiatr Serv. 2014 Jul;65(7):881-7.

6. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 Supp 4:1-46; quiz 47-8.   

7. Barbui C, Kikkert M, Mazzi MA, et al. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009;42(5):311-17.

8. Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18.

9. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy: 18-month follow-up. Br J Psychiatry. 1998 May;172:413–19.

10. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002;159(10):1653–64.